Paul Scholl

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

Kim Papp, Andrew Blauvelt, Michael Bukhalo et al. · New England Journal of Medicine · 2017 · 504 citations · Full text

The X-Linked Hyper-IgM Syndrome

Jerry A. Winkelstein, Mary C. Marino, Hans D. Ochs et al. · Medicine · 2003 · 503 citations

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Brian G. Feagan, William J. Sandborn, Geert D’Haens et al. · The Lancet · 2017 · 435 citations · Full text

Inflammation, Rheumatology, Placebo-controlled Phase 2 +8

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Dominique Baeten, Mikkel Østergaard, James Cheng‐Chung Wei et al. · Annals of the Rheumatic Diseases · 2018 · 359 citations · Full text

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

James G. Krueger, Laura K. Ferris, Alan Menter et al. · Journal of Allergy and Clinical Immunology · 2015 · 246 citations

Immunology, Clinical Trials, Biomarker Results +8